Webinar

Antibody Drug Conjugate Development and Manufacture

Published

Format: External webinar | Document type: Webinar

Antibody Drug Conjugate Development and Manufacture
With the recent approvals of brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla,T-DM1), antibody–drug conjugates (ADCs)are a rapidly growing area in oncology with great potential. Development and manufacture of ADCs can be a challenge with the requirement to handle both biologics and highly potent small molecule toxins. This webinar will look at some of the issues with developing and manufacturing ADCs

Speakers

Gary Marshallsay Gary Marshallsay Programme Manager
Piramal Healthcare

Mark Wright Mark Wright Site Lead
Piramal Healthcare

Supplier info centre